Skip to main content
Clinical Trials/IRCT20200322046833N1
IRCT20200322046833N1
Completed
Phase 3

Evaluation of the efficacy and safety of Umifenovir in the treatment of hospitalized patients with covid-19: A randomized clinical trial

Center for Progress and Development of Iran0 sites100 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Center for Progress and Development of Iran
Enrollment
100
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Center for Progress and Development of Iran

Eligibility Criteria

Inclusion Criteria

  • Age \>18 years old
  • Patients with a probable and definitive diagnosis of COVID\-19 who are candidates for hospitalization and receiving antiviral regimens.
  • Presence of at least one clinical sign (including fever, chills, cough, myalgia) with positive virologic specimen or imaging findings for COVID\-19

Exclusion Criteria

  • Patient or fellows' dissatisfaction with entering or continuing the study
  • History or any signs of hypersensitivity to umifenovir
  • Pregnancy and lactation

Outcomes

Primary Outcomes

Not specified

Similar Trials